Y Intercept (Hong Kong) LTD Nektar Therapeutics Transaction History

Y Intercept (Hong Kong) LTD

  • $1.58 Billion
  • Q3 2024

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024
BUY
$0.49 - $0.96 $62,506 - $122,461
127,564 New
127,564 $118,000
Q2 2023

Aug 14, 2023
BUY
$0.53 - $1.03 $165,361 - $321,363
312,003 New
312,003 $180,000
Q4 2021

Feb 14, 2022
SELL
$10.83 - $18.41 $115,718 - $196,710
-10,685 Closed
0 $0
Q3 2021

Nov 15, 2021
BUY
$13.07 - $18.84 $139,652 - $201,305
10,685 New
10,685 $192,000
Q1 2021

May 12, 2021
SELL
$16.56 - $25.46 $268,950 - $413,495
-16,241 Closed
0 $0
Q4 2020

Feb 05, 2021
BUY
$15.77 - $19.03 $256,120 - $309,066
16,241 New
16,241 $291,000

Others Institutions Holding NKTR

# of Institutions
147
Shares Held
139M
Call Options Held
32.6K
Put Options Held
14.1K
View Full List

About NEKTAR THERAPEUTICS

NKTR Quotes by TradingView
  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $201M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Y Intercept (Hong Kong) LTD Portfolio

Follow Y Intercept (Hong Kong) LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Y Intercept (Hong Kong) LTD, based on Form 13F filings with the SEC.

News

Stay updated on Y Intercept (Hong Kong) LTD with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email